$1.46
+0.02 (+1.39%)
Open$1.43
Previous Close$1.44
Day High$1.46
Day Low$1.41
52W High$2.68
52W Low$0.84
Volume—
Avg Volume47.2K
Market Cap6.56M
P/E Ratio—
EPS$-2.88
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,565.8% upside
Current
$1.46
$1.46
Target
$38.92
$38.92
$24.59
$38.92 avg
$51.00
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 555.8K | 518.1K | 501.1K |
| Net Income | 113.5K | 116.0K | 100.3K |
| Profit Margin | 20.4% | 22.4% | 20.0% |
| EBITDA | 245.4K | 221.0K | 210.9K |
| Free Cash Flow | 70.8K | 77.8K | 93.1K |
| Rev Growth | -5.3% | +6.0% | -5.8% |
| Debt/Equity | 0.43 | 0.40 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |